The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut spending and the U.S. PTO withdrew a controversial proposed patent rule.
The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut spending and the U.S. PTO withdrew a controversial proposed patent rule.
